We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Centessa Pharmaceuticals PLC | NASDAQ:CNTA | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.54 | -3.36% | 15.54 | 15.00 | 16.88 | 16.26 | 15.44 | 16.08 | 365,616 | 21:02:00 |
The NASDAQ Biotechnology Index contains securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. More information about the Index can be found at https://indexes.nasdaqomx.com/index/overview/NBI.
About Centessa PharmaceuticalsCentessa Pharmaceuticals plc aims to bring impactful new medicines to patients by combining the strengths of an asset-centric model with the benefits of scale and diversification typical of larger R&D organizations. The asset-centric model refers to a highly specialized, singular-focused company that is led by a team of well-recognized subject matter experts. Centessa’s asset-centric companies’ programs range from discovery-stage to late-stage development and include diverse therapeutic areas such as oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology. For more information, visit www.centessa.com.
Contacts:
Investors: Jennifer Porcelli, Head of Investor Relations Centessa Pharmaceuticals jennifer.porcelli@centessa.com
Media: Dan Budwick, 1AB dan@1abmedia.com
1 Year Centessa Pharmaceuticals Chart |
1 Month Centessa Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions